載入中
NASDAQHealthcareBiotechnology
最新資料
US$60.41
−US$1.07 · -1.74%
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
一般交易時段
US$60.41
−US$1.07 · -1.74%
盤中時間採用ET。市場資料可能有所延遲。
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
日內區間
目前US$60.41
52週區間
目前US$60.41
盤中時間採用ET。市場資料可能有所延遲。
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
日內區間
目前US$60.41
52週區間
目前US$60.41
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8.29億 USD | 355.1萬 USD | 2.41億 USD | 2.43億 USD | 1.38億 USD |
| 銷貨成本 | — | 1859.5萬 USD | 1249.3萬 USD | 1042.1萬 USD | — |
| 毛利 | 8.29億 USD | −1504.4萬 USD | 2.28億 USD | 2.33億 USD | 1.38億 USD |
| 研究與開發 | 6.07億 USD | 4.89億 USD | 3.42億 USD | 2.89億 USD | 2.06億 USD |
| 銷售、一般及管理費用 | 1.22億 USD | 9682萬 USD | 9093.2萬 USD | 1.24億 USD | 8098.1萬 USD |
| 營業費用 | 7.31億 USD | 5.86億 USD | 4.33億 USD | 4.11億 USD | 2.87億 USD |
| 利息收入 | 3728.9萬 USD | 2272萬 USD | 1529.9萬 USD | 503.3萬 USD | 612萬 USD |
| 利息支出 | 8936.1萬 USD | 3235.2萬 USD | 1832.6萬 USD | — | — |
| 折舊和攤銷 | 2392.8萬 USD | 1859.5萬 USD | 1249.3萬 USD | 1042.1萬 USD | 826.7萬 USD |
| 營業利益 | 9834.6萬 USD | −6.01億 USD | −2.05億 USD | −1.79億 USD | −1.49億 USD |
| 淨利 | −163.1萬 USD | −5.99億 USD | −2.05億 USD | −1.76億 USD | −1.41億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$100.63
上漲空間 66.58%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2011年11月17日 | 1:10 | — | — |
股票分割 | 2004年1月15日 | 1:65 | — | — |
已生效 2011年11月17日
1:10
已生效 2004年1月15日
1:65
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.51億0.01%2.3兆 USD0.03%US$379.71-0.35%
iShares Core S&P Mid-Cap ETFIJH3.12億0.26%1240.72億 USD0.05%US$72.49-0.37%
Vanguard Morningstar Small-Cap ETFVB2.54億0.14%1853億 USD0.03%US$285.58-0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK1.46億0.32%447億 USD0.05%US$339.84-0.70%
Vanguard Extended Market ETFVXF1.35億0.14%954億 USD0.05%US$232.13-0.58%
State Street SPDR S&P Biotech ETFXBI1.15億1.12%100.75億 USD0.35%US$148.13-1.40%
Invesco S&P MidCap Momentum ETFXMMO1.11億1.53%72.53億 USD0.34%US$147.15-0.79%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY6437萬0.25%259.8億 USD0.23%US$661.06-0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Core S&P Mid-Cap ETFIJHVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIInvesco S&P MidCap Momentum ETFXMMOState Street SPDR S&P MIDCAP 400 ETF TrustMDYAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
